Premium
Anagrelide influences thrombotic risk, and prolongs progression‐free and overall survival in essential thrombocythaemia vs hydroxyurea plus aspirin
Author(s) -
Kellner Adam,
Dombi Peter,
Illes Arpad,
Demeter Judit,
Homor Lajos,
Ercsei Ibolya,
Simon Zsofia,
Karadi Eva,
Herczeg Jozsef,
Gy Korom Viktoria,
Gasztonyi Zoltan,
Szerafin Laszlo,
Udvardy Miklos,
Egyed Miklos
Publication year - 2020
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/ejh.13459
Subject(s) - anagrelide , aspirin , medicine , gastroenterology , incidence (geometry) , thrombocytosis , hydroxycarbamide , surgery , chemotherapy , essential thrombocythemia , platelet , physics , optics
Abstract Objective We report an extension study of patients with essential thrombocythaemia (ET) in the Hungarian Myeloproliferative Neoplasm (HUMYPRON) Registry, which demonstrated that over 6 years anagrelide significantly decreased the number of patients experiencing minor arterial and minor venous thrombotic events (TEs) vs hydroxyurea+aspirin. Methods Data on patients with ET were collected through completion of a questionnaire developed according to 2008 WHO diagnostic criteria and with regard to Landolfi, Tefferi and IPSET criteria for thrombotic risk. Data were entered into the registry from 14 haematological centres. TEs, secondary malignancies, disease progression and survival were compared between patients with ET treated with anagrelide (n = 116) and with hydroxyurea+aspirin (n = 121). Results Patients were followed for (median) 10 years. A between‐group difference in the number of patients with TEs was observed (25.9% anagrelide vs 38.0% hydroxyurea+aspirin; P = .052). Minor arterial events were more frequently reported in the hydroxyurea+aspirin group ( P < .001); there were marginally more reports of major arterial events in the anagrelide group ( P = .049). TE prior to diagnosis was found to significantly influence TE incidence ( P > .001). Progression‐free survival ( P = .004) and survival ( P = .001) were significantly increased for the anagrelide group vs hydroxyurea+aspirin. Conclusions Anagrelide reduced TEs, and increased progression‐free and overall survival vs hydroxyurea+aspirin over (median) 10 years.